Neuroprotection in Glaucoma: Towards Clinical Trials and Precision Medicine
Tasneem Z Khatib, Keith R Martin
CURRENT EYE RESEARCH | TAYLOR & FRANCIS INC | Published : 2019
Purpose: The eye is currently at the forefront of translational medicine and therapeutics. However, despite advances in technology, primary open-angle glaucoma remains the leading cause of irreversible blindness worldwide. Traditional intraocular pressure (IOP)-lowering therapies are often not sufficient to prevent progression to blindness, even in patients with access to high-quality healthcare. Neuroprotection strategies, which aim to boost the ability of target cells to withstand a pathological insult, have shown significant promise in animal models but none have shown clinically relevant efficacy in human clinical trials to date. We sought to evaluate the current status of neuroprotectio..View full abstract
This work was supported by the Fight for Sight UK; Jukes Glaucoma Research Fund; Addenbrooke's Charitable Trust; MRC to the Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute; Cambridge Eye Trust; HB Allen Charitable Trust; Wellcome Trust.